Benzinga · Mar 2, 2026
GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent decrease over losses of $(1.66) per share from the same period last year.
GT
NASDAQ · GTBP
GT Biopharma, Inc.
Healthcare · Biotechnology
$5.27
Down-$0.44 (-8.35%)
Updated Nov 4, 2026, 8:16 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.84M
- P/E ratio
- -0.27
- Dividend yield
- 0.00%
- 52-week range
- $0.26 – $11.98
- Volume
- 41.65K
- Avg. volume
- 2.07M
Price performance · GTBP
GTBP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
GTBP closed at $5.27 after 21 trading sessions, down 17.27% for the selected period.
- Last close
- $5.27
- Period change
- -17.27%
- Period low
- $5.07
- Period high
- $7.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $5.16 | $5.32 | $5.05 | $5.27 | 41.65K |
| Nov 2, 2026 | $5.35 | $5.3988 | $5.11 | $5.13 | 33.59K |
| Oct 30, 2026 | $5.47 | $5.535 | $5.30 | $5.32 | 20.27K |
| Oct 29, 2026 | $5.61 | $5.69 | $5.46 | $5.60 | 57.02K |
| Oct 28, 2026 | $5.39 | $5.69 | $5.32 | $5.51 | 54.78K |
| Oct 27, 2026 | $5.56 | $5.671 | $5.18 | $5.58 | 102.42K |
| Oct 26, 2026 | $5.49 | $5.78 | $5.07 | $5.07 | 178.78K |
| Oct 23, 2026 | $5.58 | $5.70 | $5.31 | $5.46 | 63.92K |
| Oct 22, 2026 | $5.37 | $5.57 | $5.28 | $5.52 | 69.42K |
| Oct 21, 2026 | $6.81 | $6.90 | $5.31 | $5.41 | 170.84K |
| Oct 20, 2026 | $6.63 | $7.49 | $6.63 | $7.31 | 49.37K |
| Oct 19, 2026 | $7.17 | $7.17 | $6.69 | $6.69 | 28.77K |
| Oct 16, 2026 | $7.14 | $7.32 | $6.86 | $7.03 | 55.29K |
| Oct 15, 2026 | $6.50 | $7.40 | $6.50 | $7.36 | 63.08K |
| Oct 14, 2026 | $6.44 | $6.44 | $5.86 | $6.21 | 42.15K |
| Oct 13, 2026 | $7.50 | $7.50 | $6.3282 | $6.50 | 29.57K |
| Oct 12, 2026 | $6.79 | $7.05 | $6.50 | $6.80 | 37.96K |
| Oct 9, 2026 | $5.96 | $6.68 | $5.8269 | $6.68 | 43.38K |
| Oct 8, 2026 | $6.20 | $6.22 | $5.80 | $5.96 | 31.77K |
| Oct 7, 2026 | $6.30 | $6.47 | $6.20 | $6.20 | 19.17K |
| Oct 6, 2026 | $6.31 | $6.45 | $6.20 | $6.37 | 22.4K |
Latest GTBP news
The latest Smart Investors Daily articles mentioning GTBP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GTBP research
Overview
Company profile and research snapshot.
Company profile
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 2, 2024 | Roth MKM | Buy | — |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2023 | EF Hutton | Hold | — |
| Jun 5, 2023 | HC Wainwright & Co. | Buy | — |
| May 17, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026
Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalents of approximately $7 million as of December 31, 2025, and an unaudited proforma cash balance as of January 31, 2026 of
Benzinga · Feb 12, 2026
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · Feb 3, 2026
GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express B7-H3Unaudited proforma cash balance as of January 31, 2026 of approximately
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
